Cargando…

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result

Background: Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. Objective: To discover a plasma proteomic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westwood, Sarah, Baird, Alison L., Hye, Abdul, Ashton, Nicholas J., Nevado-Holgado, Alejo J., Anand, Sneha N., Liu, Benjamine, Newby, Danielle, Bazenet, Chantal, Kiddle, Steven J., Ward, Malcolm, Newton, Ben, Desai, Keyur, Tan Hehir, Cristina, Zanette, Michelle, Galimberti, Daniela, Parnetti, Lucilla, Lleó, Alberto, Baker, Susan, Narayan, Vaibhav A., van der Flier, Wiesje M., Scheltens, Philip, Teunissen, Charlotte E., Visser, Pieter Jelle, Lovestone, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297196/ https://www.ncbi.nlm.nih.gov/pubmed/30618716 http://dx.doi.org/10.3389/fnagi.2018.00409

Ejemplares similares

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

ANMerge: A Comprehensive and Accessible Alzheimer’s Disease Patient-Level Dataset
por: Birkenbihl, Colin, et al.
Publicado: (2021)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
por: Winchester, Laura M., et al.
Publicado: (2018)

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
por: Westwood, Sarah, et al.
Publicado: (2017)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
por: Cullen, Breda, et al.
Publicado: (2018)

Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
por: Voyle, N, et al.
Publicado: (2016)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
por: Voyle, Nicola, et al.
Publicado: (2015)

Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
por: Farrar, Gill, et al.
Publicado: (2019)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Predicting progression to Alzheimer’s disease with human hippocampal progenitors exposed to serum
por: Maruszak, Aleksandra, et al.
Publicado: (2023)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Associations Between Brain Volumes and Cognitive Tests with Hypertensive Burden in UK Biobank
por: Newby, Danielle, et al.
Publicado: (2021)

The relationship between isolated hypertension with brain volumes in UK Biobank
por: Newby, Danielle, et al.
Publicado: (2022)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer’s Disease Therapeutic Development
por: Nevado-Holgado, Alejo J., et al.
Publicado: (2019)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

Effective connectivity of the subthalamic nucleus–globus pallidus network during Parkinsonian oscillations
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2014)

Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers
por: Miki, Takami, et al.
Publicado: (2017)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

Validation of UK Biobank data for mental health outcomes: A pilot study using secondary care electronic health records
por: Li, Zhenpeng, et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
por: Shi, Liu, et al.
Publicado: (2021)

NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology
por: Rojo, Ana I., et al.
Publicado: (2017)

Unreliable Evidence: 2 Sources of Uncertainty During Perceptual Choice
por: Michael, Elizabeth, et al.
Publicado: (2015)

Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice
por: Martín-Sánchez, Ana, et al.
Publicado: (2021)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid
por: Winchester, Laura, et al.
Publicado: (2022)

Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods
por: Battle, Mark R., et al.
Publicado: (2018)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n73hmff5di991ulknvndo3rd3q